Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic

Kyle LaHucik

Senior Reporter

A small Swiss drug developer is being scooped up for its pipeline of three antibody-drug conjugates that offer a next-generation approach to the area of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Trump’s HHS defends Biden-era stance on 340B rebate models

FDA staff return to White Oak campus en masse after Trump administration push

Incyte's stock sinks as pivotal skin disease data disappoint

George Church spinout developing genomically recoded organisms cuts most employees

Post-Hoc: Kennedy's anti-vaccine actions shouldn't surprise anyone

AstraZeneca to buy cell therapy startup for $425M upfront

Ot­suka's Tai­ho buys Swiss start­up Araris with three AD­Cs near­ing the clin­ic

Senior Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic